{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enzyme+testing&page=8", "query": { "intervention": "Enzyme testing", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 174, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enzyme+testing&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enzyme+testing&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T13:32:31.786Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03965689", "title": "Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Lung Non-Small Cell Squamous Carcinoma", "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Lung Non-Squamous Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-04-16", "completion_date": "2027-03-20", "has_results": true, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-28T13:32:31.786Z", "location_count": 10, "location_summary": "Los Angeles, California • Newport Beach, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03965689" }, { "nct_id": "NCT07228624", "title": "Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic/Myeloproliferative Neoplasm", "Primary Myelofibrosis", "Secondary Myelofibrosis" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "JAK Inhibitor", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 50, "start_date": "2026-02-04", "completion_date": "2030-09-01", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-28T13:32:31.786Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07228624" }, { "nct_id": "NCT03952494", "title": "Individualizing Antidepressant Treatment Using Pharmacogenomics and EHR-driven Clinical Decision Support", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depression" ], "interventions": [ { "name": "Genomind®Professional PGx Express TM", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 0, "start_date": "2022-03-01", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2021-11-08", "last_synced_at": "2026-10-28T13:32:31.786Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03952494" }, { "nct_id": "NCT04175912", "title": "Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cholangiocarcinoma", "Metastatic Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Cholangiocarcinoma", "Unresectable Hepatocellular Carcinoma", "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-03-16", "completion_date": "2027-09-03", "has_results": true, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-28T13:32:31.786Z", "location_count": 419, "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 254 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04175912" }, { "nct_id": "NCT05659147", "title": "Imaging Biomarkers of Pancreatic Function and Disease", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pancreatitis", "Diabetes Mellitus" ], "interventions": [ { "name": "Research MRI without administration of intravenous secretin", "type": "DIAGNOSTIC_TEST" }, { "name": "Research MRI with administration of intravenous secretin", "type": "DIAGNOSTIC_TEST" }, { "name": "Genetic Sequencing", "type": "GENETIC" }, { "name": "Blood Tests", "type": "DIAGNOSTIC_TEST" }, { "name": "Stool Tests", "type": "DIAGNOSTIC_TEST" }, { "name": "Survey Completion", "type": "OTHER" }, { "name": "Endoscopic pancreatic function tests (ePFTs)", "type": "DIAGNOSTIC_TEST" }, { "name": "Secretin", "type": "DRUG" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "GENETIC", "OTHER", "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "5 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "5 Years to 21 Years" }, "enrollment_count": 195, "start_date": "2023-01-18", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-28T13:32:31.786Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05659147" }, { "nct_id": "NCT07220187", "title": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Richter Syndrome", "Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma", "Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Rituximab and Hyaluronidase Human", "type": "BIOLOGICAL" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2026-08-04", "completion_date": "2036-10", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-28T13:32:31.786Z", "location_count": 62, "location_summary": "Irvine, California • Laguna Hills, California • Orange, California + 48 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07220187" }, { "nct_id": "NCT03727932", "title": "VioOne HIV Profile Supplemental Assay", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VioOne HIV Profile Supplemental Assay", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Avioq, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 757, "start_date": "2018-01-03", "completion_date": "2018-04-11", "has_results": false, "last_update_posted_date": "2018-11-02", "last_synced_at": "2026-10-28T13:32:31.786Z", "location_count": 1, "location_summary": "Research Triangle Park, North Carolina", "locations": [ { "city": "Research Triangle Park", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03727932" }, { "nct_id": "NCT01602016", "title": "A Folinic Acid Intervention for Autism Spectrum Disorders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism Spectrum Disorder", "Autistic Disorder", "Autism", "Asperger's Syndrome", "Pervasive Development Disorders" ], "interventions": [ { "name": "Folinic Acid and placebo", "type": "DRUG" }, { "name": "Folinic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "14 Years", "sex": "ALL", "summary": "3 Years to 14 Years" }, "enrollment_count": 99, "start_date": "2012-05", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-10-17", "last_synced_at": "2026-10-28T13:32:31.786Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01602016" }, { "nct_id": "NCT00668902", "title": "Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "[13C]Pantoprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 25, "start_date": "2007-03", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2014-12-17", "last_synced_at": "2026-10-28T13:32:31.786Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00668902" }, { "nct_id": "NCT04821245", "title": "Defining Normal Postoperative Magnetic Resonance Imaging After Total Knee Arthroplasty", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Local Anesthetic Complication", "Local Anesthetic Drug Adverse Reaction" ], "interventions": [], "intervention_types": [], "sponsor": "Benaroya Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 36, "start_date": "2018-12-04", "completion_date": "2019-08-02", "has_results": true, "last_update_posted_date": "2021-05-25", "last_synced_at": "2026-10-28T13:32:31.786Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04821245" } ] }